Catatan sumber primer
PenentuHasil topline
Verastem: hasil topline Fase 3 RAMP 301 diperkirakan pada pertengahan 2027
Presentasi korporat Maret 2026 menyatakan bahwa uji coba konfirmatori RAMP 301 Phase 3 avutometinib + defactinib versus terapi pilihan investigator pada LGSOC rekuren akan melaporkan data topline pada pertengahan 2027. Pembacaan ini dimaksudkan untuk mengonfirmasi hasil RAMP 201 dan berpotensi memperluas indikasi yang disetujui untuk AVMAPKI FAKZYNJA CO-PACK tanpa memandang status mutasi KRAS.
Fakta utama
- Diajukan
- 4 Mar 2026, 21.15
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
VSTMVerastem- Aset
- avutometinib
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 tm267866d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A R C H 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC), the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc
Selengkapnya tentang aset ini
Minor
6 Agu 2026
23.33
VSTMVerastemVerastem menyajikan pembaruan korporat tentang AVMAPKI FAKZYNJA CO-PACK